Straits Times Index
3,323.20 -6.89 (-0.21%) S&P 500
5,306.04 +1.32 (+0.02%) Dow
38,852.86 -216.74 (-0.55%) Nasdaq
17,019.88 +99.08 (+0.59%) Bitcoin USD
67,844.27 -655.33 (-0.96%) CMC Crypto 200
1,463.61 -21.08 (-1.42%)
AstraZeneca PLC (AZNCF)
| Previous close | 159.12 |
| Open | 153.01 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 151.98 - 159.84 |
| 52-week range | 118.16 - 159.84 |
| Volume | |
| Avg. volume | 3,406 |
| Market cap | 245.713B |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | 39.23 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.86 (1.80%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | N/A |
- Benzinga
Why Is AstraZeneca Stock Trading Lower On Tuesday?
On Tuesday, AstraZeneca Plc (NASDAQ:AZN) said the survival results did not reach statistical significance in the overall trial population in the TROPION-Lung01 phase 3 trial. Topline overall survival (OS) results from the TROPION-Lung01 phase 3 trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favored datopotamab deruxtecan (Dato-DXd) compared to docetaxel for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients treated wi
- Zacks
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- Zacks
Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
AstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer (PFE) announces a multi-year, multi-phase cost reduction program.
